Table 1 Clinical characteristics of 25 patients with RA aortitis
From: Rheumatoid arthritis-associated aortitis: a case report and literature review
Case | Ref | Age/Sex | Disease duration of RA | Extra-aortic involvement of arteritis | Pathology of Aortitis | Rheumatoid nodule | RF | Type of HLA | RA treatment | Aortitis treatment | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Granuloma | Giant cells | Atherosclerosis | ||||||||||
1 | 6 | 68/F | ND | ND | – | + | – | ND | ND | ND | NSAIDs | NSAIDs |
2 | 6 | 71/F | ND | ND | – | + | + | ND | ND | ND | NSAIDs | NSAIDs |
3 | 7 | 63/F | 23 | – | ND | ND | + | ND | + | ND | ND | Steroid |
4 | 7 | 65/F | 10 | ND | ND | ND | + | + | + | ND | ND | Steroid |
5 | 8 | 16/F | 0 | + | ND | ND | ND | – | – | ND | Steroid | NSAIDs |
6 | 9 | 49/F | 5 | + | + | + | – | + | + | ND | NSAIDs, Gold, PSL | Digitalis |
7 | 10 | 37/F | −11* | – | ND | ND | ND | + | + | DR4 | NSAIDs, CQ, Gold | PSL 40 mg |
8 | 11 | 53/F | 0 | + | ND | ND | ND | – | – | ND | NSAIDs, HCQ | PSL 60 mg |
9 | 12 | 50/F | 0 | – | – | – | – | – | + | ND | NSAIDs | – |
10 | 13 | 46/M | 9 | + | – | – | + | + | + | ND | Aspirin | – |
11 | 13 | 52/F | 26 | + | – | – | + | + | + | ND | Steroid, Aspirin | – |
12 | 13 | 60/M | 12 | + | – | – | + | + | + | ND | Steroid, HCQ, Gold, CYC | – |
13 | 13 | 61/F | 11 | – | + | – | + | + | + | ND | Steroid, Gold, Aspirin | High-dose steroid |
14 | 13 | 61/F | 3 | – | + | – | + | + | + | ND | Steroid, HCQ, Gold | – |
15 | 13 | 64/F | 3 | – | + | – | + | + | + | ND | Steroid, HCQ, Gold | – |
16 | 13 | 67/M | 2 | + | – | – | + | + | + | ND | Steroid | – |
17 | 13 | 68/M | 21 | + | + | – | + | + | + | ND | Steroid, HCQ | – |
18 | 13 | 69/M | 1 | + | + | – | + | + | + | ND | Steroid, Gold, SASP | – |
19 | 13 | 82/F | 8 | + | – | – | – | – | – | ND | Steroid, HCQ | Low-dose steroid |
20 | 14 | 44/M | ND | + | ND | ND | ND | + | + | ND | Steroid, SASP | PSL 100 mg, IVCY 5 mg/kg |
21 | 15 | 64/F | 4 | – | ND | ND | + | + | + | DR2,12(5) | ND | PSL 10 mg |
22 | 16 | 36/F | 2 | – | ND | ND | ND | ND | + | DR4,1 | SASP, MTX | PSL 50 mg |
23 | 17 | 49/F | 1 | – | ND | ND | ND | – | + | ND | Steroid, MTX, LEF | PSL 40 mg, bosentan |
24 | 18 | 43/F | ND | – | ND | ND | ND | – | + | ND | MTX, ADA | mPSL 250 mg, PSL 40 mg |
25 | Present case | 73/F | 4 | + | ND | ND | + | – | + | B51, B52 | SASP, TAC | PSL 30 mg |